checkAd

     173  0 Kommentare 89bio to Present 48-Week Data from ENLIVEN Phase 2b Pegozafermin Trial in Metabolic Dysfunction-Associated Steatohepatitis (MASH) at EASL International Liver Congress

    -Poster presentation selected for the EASL Poster Tour, a dedicated discussion session-

    SAN FRANCISCO, May 22, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that data from the 48-week extension phase of the Phase 2b ENLIVEN trial evaluating pegozafermin in patients with metabolic dysfunction-associated steatohepatitis (MASH) with fibrosis will be presented in an oral and poster presentation at the European Association for the Study of the Liver (EASL) Congress to be held June 5 to 8, 2024 in Milan, Italy.

    “These data, which are being presented for the first time in a scientific setting, establish pegozafermin as the first FGF21 analog candidate to demonstrate positive, sustained benefits over a 48-week period in patients with advanced MASH,” said Hank Mansbach, Chief Medical Officer of 89bio. “In addition, these data highlight the observed long-term efficacy, tolerability and sustained improvement in key liver health markers, that we aim to confirm in our ongoing Phase 3 program.”

    Presentation details are as follows:

    Lesen Sie auch

    Abstract Title: Week 48 results from the Phase 2b ENLIVEN extension study investigating pegozafermin for the treatment of metabolic dysfunction-associated steatohepatitis with fibrosis
    Abstract Number: 943
    Format: Oral presentation
    Presenting Author: Rohit Loomba, M.D., MHSc, Chief of the Division of Gastroenterology and Hepatology at University of California San Diego School of Medicine, and lead investigator of the ENLIGHTEN program
    Presentation Date and Time: Saturday, June 8th 10:45-12:00 CET
    About the Abstract: The Phase 2b ENLIVEN trial evaluated the efficacy and safety of pegozafermin in MASH patients with biopsy-proven F2/F3 fibrosis. After the main study, patients began a 24-week blinded extension phase for a total of 48 weeks of treatment. At week 48, both the 30mg weekly and 44mg every-two-week dosing schedules of pegozafermin demonstrated statistically significant improvements across key markers of liver health. The benefits observed at week 48 were consistent with the results observed at week 24, indicating sustained benefits over time.

    Seite 1 von 5



    globenewswire
    0 Follower
    Autor folgen

    Verfasst von globenewswire
    89bio to Present 48-Week Data from ENLIVEN Phase 2b Pegozafermin Trial in Metabolic Dysfunction-Associated Steatohepatitis (MASH) at EASL International Liver Congress -Poster presentation selected for the EASL Poster Tour, a dedicated discussion session-SAN FRANCISCO, May 22, 2024 (GLOBE NEWSWIRE) - 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and …